GABARAPL1 and Parkinson disease: Moreover, GABARAPL1 can interact with α-synuclein, a protein shown to form protein aggregates and deleterious lewy bodies in Parkinson's disease, and displays a higher binding affinity for α-synuclein oligomers compared to monomers [41].